Browse > Article
http://dx.doi.org/10.4333/KPS.2010.40.S.033

Hyaluronic Acid in Drug Delivery Systems  

Jin, Yu-Jin (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University)
Ubonvan, Termsarasab (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University)
Kim, Dae-Duk (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University)
Publication Information
Journal of Pharmaceutical Investigation / v.40, no.spc, 2010 , pp. 33-43 More about this Journal
Abstract
Hyaluronic acid (HA) is a biodegradable, biocompatible, non-toxic, non-immunogenic and non-inflammatory linear polysaccharide, which has been used for various medical applications including arthritis treatment, wound healing, ocular surgery, and tissue augmentation. Because of its mucoadhesive property and safety, HA has received much attention as a tool for drug delivery system development. It has been used as a drug delivery carrier in both nonparenteral and parenteral routes. The nonparenteral application includes the ocular and nasal delivery systems. On the other hand, its use in parenteral systems has been considered important as in the case of sustained release formulation of protein drugs through subcutaneous injection. Particles and hydrogels by various methods using HA and HA derivatives as well as by conjugation with other polymer have been the focus of many studies. Furthermore, the affinity of HA to the CD44 receptor which is overexpressed in various tumor cells makes HA an important means of cancer targeted drug delivery. Current trends and development of HA as a tool for drug delivery will be outlined in this review.
Keywords
Hyaluronic acid; Biodegradable polymer; Protein delivery; Gene delivery; Sustained delivery;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Varma, R., Varma, R., Allen, W., Wardi, A., 1975. Human umbilical cord hyaluronate neutral sugar content and carbohydrateprotein linkage studies. Biochimica et Biophysica Acta (BBA)-General Subjects 399, 139-144.   DOI
2 West, D., Hampson, I., Arnold, F., Kumar, S., 1985. Angiogenesis induced by degradation products of hyaluronic acid. Science 228, 1324-1326.   DOI
3 Wieland, J., Houchinray, T., Shea, L., 2007. Non-viral vector delivery from PEG-hyaluronic acid hydrogels. Journal of Controlled Release 120, 233-241.   DOI
4 Wilson, A., Zhou, W., Champion, H., Alber, S., Tang, Z., Kennel, S., Watkins, S., Huang, L., Pitt, B., Li, S., 2005. Targeted delivery of oligodeoxynucleotides to mouse lung endothelial cells in vitro and in vivo. Molecular Therapy 12, 510-518.   DOI
5 Xie, Y., Aillon, K.L., Cai, S., Christian, J.M, Davies NM, Berkland CJ, Forrest ML. 2010. Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer. International Journal of Pharmaceutics 392, 156-163.   DOI
6 Xu, P., Quick, G.K., Yeo, Y., 2009. Gene delivery through the use of a hyaluronate-associated intracellularly degradable crosslinked polyethyleneimine. Biomaterials 30, 5834-5843.   DOI
7 Yenice, I., Mocan, M., Palaska, E., Bochot, A., Bilensoy, E., Vural, I., Irkec, M., Atillahincal, A., 2008. Hyaluronic acid coated poly--caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea. Experimental Eye Research 87, 162-167.   DOI
8 Sun, X., Ma, P., Cao, X., Ning, L., Tian, Y., Ren, C., 2009. Positive hyaluronan/PEI/DNA complexes as a target-specific intracellular delivery to malignant breast cancer. Drug Delivery 16, 357-362.   DOI
9 Rydell, N., Balazs, E., 1971. Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and on granulation tissue formation. Clinical Orthopaedics and Related Research 80, 25.   DOI
10 Saraf, A., Hacker, M., Sitharaman, B., Grande-Allen, K., Barry, M., Mikos, A., 2008. Synthesis and conformational evaluation of a novel gene delivery vector for human mesenchymal stem cells. Biomacromolecules 9, 818-827.   DOI
11 Schiffelers, R., Ansari, A., Xu, J., Zhou, Q., Tang, Q., Storm, G., Molema, G., Lu, P., Scaria, P., Woodle, M., 2004. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic acids research 32, e149.   DOI
12 Segura, T., 2005. DNA delivery from hyaluronic acid-collagen hydrogels via a substrate-mediated approach. Biomaterials 26, 1575-1584.   DOI
13 Shim, W., Yoo, J., Bae, Y., Lee, D., 2005. Novel injectable pH and temperature sensitive block copolymer hydrogel. Biomacromolecules 6, 2930-2934.   DOI
14 Shu, X., Liu, Y., Luo, Y., Roberts, M., Prestwich, G., 2002. Disulfide cross-linked hyaluronan hydrogels. Biomacromolecules 3, 1304-1311.   DOI
15 Singh, M., Briones, M., O'Hagan, D., 2001. A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. Journal of Controlled Release 70, 267-276.   DOI
16 Sintzel, M., Bernatchez, S., Tabatabay, C., Gurny, R., 1996. Biomaterials in ophthalmic drug delivery. European journal of pharmaceutics and biopharmaceutics 42, 358-374.
17 Morimoto, K., Yamaguchi, H., Iwakura, Y., Morisaka, K., Ohashi Y., Nakai, Y., 1991. Effects of viscous hyaluronate-sodium solutions on the nasal absorption of vasopressin and an analogue. Pharmaceutical research 8, 471-474.   DOI
18 Luo, Y., Bernshaw, N., Lu, Z., Kopecek, J., Prestwich, G., 2002. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates. Pharmaceutical research 19, 396-402.   DOI
19 Lin, Q.-K., Ren, K.-F., Ji, J., 2009. Hyaluronic acid and chitosan-DNA complex multilayered thin film as surface-mediated nonviral gene delivery system. Colloids and Surfaces B: Biointerfaces 74, 298-303.   DOI
20 Ludwig, A., 2005. The use of mucoadhesive polymers in ocular drug delivery. Advanced drug delivery reviews 57, 1595-1639.   DOI
21 Luo, Y., Kirker, K., Prestwich, G., 2000. Cross-linked hyaluronic acid hydrogel films: new biomaterials for drug delivery. Journal of Controlled Release 69, 169-184.   DOI
22 Lutolf, M., Lauer-Fields, J., Schmoekel, H., Metters, A., Weber, F., Fields, G., Hubbell, J., 2003. Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: engineering cell-invasion characteristics. Proceedings of the National Academy of Sciences of the United States of America 100, 5413.   DOI
23 Maeda, H., Seymour, L., Miyamoto, Y., 1992. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjugate chemistry 3, 351-362.   DOI
24 Marshall, K., 2000. Intra-articular hyaluronan therapy. Current opinion in rheumatology 12, 468.   DOI
25 Matsubara, Y., Katoh, S., Taniguchi, H., Oka, M., Kadota, J., Kohno, S., 2000. Expression of CD44 Variants in Lung Cancer and Its Relationship to Hyaluronan Binding. The Journal of International Medical Research 28, 78-90.   DOI   ScienceOn
26 Mok, H., Park, J., Park, T., 2007. Antisense oligodeoxynucleotide-conjugated hyaluronic acid/protamine nanocomplexes for intracellular gene inhibition. Bioconjugate Chem 18, 1483-1489.   DOI
27 Illum, L., Farraj, N., Fisher, A., Gill, I., Miglietta, M., Benedetti, L., 1994. Hyaluronic acid ester microspheres as a nasal delivery system for insulin. Journal of Controlled Release 29, 133-141.   DOI
28 Kumar, A., Sahoo, B., Montpetit, A., Behera, S., Lockey, R., Mohapatra, S., 2007. Development of hyaluronic acid-Fe2O3 hybrid magnetic nanoparticles for targeted delivery of peptides. Nanomedicine: Nanotechnology, Biology and Medicine 3, 132-137.   DOI
29 Huh, Y., Cho, H., Yoon, I., Choi, M., Kim, J., Oh, E., Chung, S., Shim, C., Kim, D., 2010. Preparation and evaluation of spraydried hyaluronic acid microspheres for intranasal delivery of fexofenadine hydrochloride. European Journal of Pharmaceutical Sciences.
30 Hume, L., Lee, H., Benedetti, L., Sanzgiri, Y., Topp, E., Stella, V., 1994. Ocular sustained delivery of prednisolone using hyaluronic acid benzyl ester films. International Journal of Pharmaceutics 111, 295-298.   DOI
31 Ito, T., Iidatanaka, N., Niidome, T., Kawano, T., Kubo, K., Yoshikawa, K., Sato, T., Yang, Z., Koyama, Y., 2006. Hyaluronic acid and its derivative as a multi-functional gene expression enhancer: Protection from non-specific interactions, adhesion to targeted cells, and transcriptional activation. Journal of Controlled Release 112, 382-388.   DOI
32 Ito, T., Yoshihara, C., Hamada, K., Koyama, Y., 2010. DNA/polyethyleneimine/ hyaluronic acid small complex particles and tumor suppression in mice. Biomaterials 31, 2912-2918.   DOI
33 Jeong, B., Bae, Y., Kim, S., 2000. Drug release from biodegradable injectable thermosensitive hydrogel of PEG-PLGA-PEG triblock copolymers. Journal of Controlled Release 63, 155-163.   DOI   ScienceOn
34 Jeong, B., Lee, K., Gutowska, A., An, Y., 2002. % Thermogelling Biodegradable Copolymer Aqueous Solutions for Injectable Protein Delivery and Tissue Engineering. Biomacromolecules 3, 865-868.   DOI
35 Laurent, T., 1998. The chemistry, biology and medical applications of hyaluronan and its derivatives: Portland Pr.
36 Yokota, A., Ishii, G., Sugaya, Y., Nishimura, M., Saito, Y., Harigaya, K., 1999. Potential use of serum CD44 as an indicator of tumour progression in acute leukemia. Hematological Oncology 17, 161-168.   DOI
37 Yun, Y., 2004. Hyaluronan microspheres for sustained gene delivery and site-specific targeting. Biomaterials 25, 147-157.   DOI
38 Upadhyay, K.K., Bhatt, A.N, Mishra, A.K., Dwarakanath, B.S., Jain, S., Schatz, C., Le Meins, J.-F., Farooque, A., Chandraiah, G., Jain, A.K., 2010. The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly(${\gamma}$-benzyl l-glutamate)-b-hyaluronan polymersomes. Biomaterials 31, 2882-2892.   DOI
39 Kuo, J., Swann, D., Prestwich, G., 1991. Chemical modification of hyaluronic acid by carbodiimides. Bioconjugate Chemistry 2, 232-241.   DOI
40 Kyyronen, K., Hume, L., Benedetti, L., Urtti, A., Topp, E., Stella., V., 1992. Methylprednisolone esters of hyaluronic acid in ophthalmic drug delivery: in vitro and in vivo release studies. International Journal of Pharmaceutics 80, 161-169.   DOI
41 Le Bourlais, C., Acar, L., Zia, H., Sado, P., Needham, T., Leverge, R., 1998. Ophthalmic drug delivery systems--recent advances. Progress in retinal and eye research 17, 33-58.   DOI
42 Lee, B., West, B., McLemore, R., Pauken, C., Vernon, B., 2006. Insitu injectable physically and chemically gelling NIPAAmbased copolymer system for embolization. Biomacromolecules 7, 2059-2064.   DOI
43 Lee, E., Kwon, M., Na, K., Bae, J., 2007a. Protein release behavior from porous microparticle with lysozyme/hyaluronate ionic complex. Colloids and Surfaces B: Biointerfaces 55, 125-130.   DOI
44 Lee, F., Chung, J., Kurisawa, M., 2009. An injectable hyaluronic acid-tyramine hydrogel system for protein delivery. Journal of Controlled Release 134, 186-193.   DOI
45 Lee, H., Mok, H., Lee, S., Oh, Y., Park, T., 2007b. Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels. Journal of Controlled Release 119, 245-252.   DOI
46 Lim, S., Martin, G., Berry, D., Brown, M., 2000. Preparation and evaluation of the in vitro drug release properties and mucoadhesion of novel microspheres of hyaluronic acid and chitosan. Journal of Controlled Release 66, 281-292.   DOI
47 Jiang, G., Park, K., Kim, J., Kim, K., Hahn, S., 2009. Target Specific Intracellular Delivery of siRNA/PEI- HA Complex by Receptor Mediated Endocytosis. Molecular Pharmaceutics 6, 727-737.   DOI
48 Bourguignon, L., Zhu, H., Shao, L., Chen, Y., 2000. CD44 interaction with tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration. Journal of Biological Chemistry 275, 1829.   DOI
49 Brown, M., Jones, S., 2005. Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin. Journal of the European Academy of Dermatology and Venereology 19, 308-318.   DOI
50 Bucolo, C., Mangiafico, P., 1999. Pharmacological profile of a new topical pilocarpine formulation. Journal of Ocular Pharmacology and Therapeutics 15, 567-573.   DOI
51 Gurny, R., Ryser, J., Tabatabay, C., Martenet, M., Edman, P., Camber, O., 1990. Precorneal residence time in humans of sodium hyaluronate as measured by gamma scintigraphy. Graefe's archive for clinical and experimental ophthalmology 228, 510-512.   DOI
52 Hahn, S., Jelacic, S., Maier, R., Stayton, P., Hoffman, A., 2004. Anti-inflammatory drug delivery from hyaluronic acid hydrogels. Journal of Biomaterials Science, Polymer Edition 15, 1111-1119.   DOI
53 Hahn, S., Oh, E., Miyamoto, H., Shimobouji, T., 2006. Sustained release formulation of erythropoietin using hyaluronic acid hydrogels crosslinked by Michael addition. International Journal of Pharmaceutics 322, 44-51.   DOI
54 Han, S.-E., Kang, H., Shim, G.Y., Kim S.J., Choi, H.-G., Kim, J., Hahn, S.K., Oh, Y.-K., 2009. Cationic derivatives of biocompatible hyaluronic acids for delivery of siRNA and antisense oligonucleotides. Journal of Drug Targeting 17, 123-132.   DOI
55 Herbert, P., Murphy, K., Johnson, O., Dong, N., Jaworowicz, W., Tracy, M., Cleland, J., Putney, S., 1998. A large-scale process to produce microencapsulated proteins. Pharmaceutical research 15, 357-361.   DOI
56 Hirakura, T., Yasugi, K., Nemoto, T., Sato, M., Shimoboji, T., Aso, Y., Morimoto, N., Akiyoshi, K., 2009. Hybrid hyaluronan hydrogel encapsulating nanogel as a protein nanocarrier: New system for sustained delivery of protein with a chaperone-like function. Journal of Controlled Release.
57 Hornof, M., de la Fuente, M., Hallikainen, M., Tammi, R.H., Urtti, A., 2008. Low molecular weight hyaluronan shielding of DNA/PEI polyplexes facilitates CD44 receptor mediated uptake in human corneal epithelial cells. The journal of gene medicine 10, 70-80.   DOI
58 de la Fuente M., Seijo, B., Alonso, M.J., 2008b. Novel Hyaluronic Acid-Chitosan Nanoparticles for Ocular Gene Therapy. Investigative Ophthalmology & Visual Science 49, 2016-2024.   DOI
59 Horvat, S., Feher, A., Wolburg, H., Sipos, P., Veszelka, S., Toth, A., Kis, L., Kurunczi, A., Balogh, G., Kurti, L., 2009. Sodium hyaluronate as a mucoadhesive component in nasal formulation enhances delivery of molecules to brain tissue. European journal of pharmaceutics and biopharmaceutics 72, 252-259.   DOI
60 de la Fuente M., Seijo, B., Alonso, M., 2008a. Novel hyaluronan-based nanocarriers for transmucosal delivery of macromolecules. Macromolecular bioscience 8, 441-450.   DOI
61 Dollo, G., Malinovsky, J., Peron, A., Chevanne, F., Pinaud, M., Verge, R., Corre, P., 2004. Prolongation of epidural bupivacaine effects with hyaluronic acid in rabbits. International Journal of Pharmaceutics 272, 109-119.   DOI
62 Edelstein, M., Abedi, M., Wixon, J., Edelstein, R., 2004. Gene therapy clinical trials worldwide 1989-2004-an overview. The journal of gene medicine 6, 597-602.   DOI
63 Elbert, D., Pratt, A., Lutolf, M., Halstenberg, S., Hubbell, J., 2001. Protein delivery from materials formed by self-selective conjugate addition reactions. Journal of Controlled Release 76, 11-25.   DOI
64 Eliaz, R., Szoka, Jr, F., 2001. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer research 61, 2592.
65 Esposito, E., Menegatti, E., Cortesi, R., 2005. Hyaluronan-based microspheres as tools for drug delivery: a comparative study. International Journal of Pharmaceutics 288, 35-49.   DOI
66 Cascone, M., Sim, B., 1995. Blends of synthetic and natural polymers as drug delivery systems for growth hormone. Biomaterials 16, 569-574.   DOI
67 Fischer, D., Li, Y., Ahlemeyer, B., Krieglstein, J., Kissel, T., 2003. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 24, 1121-1131.   DOI
68 Goldman, C., Soroceanu, L., Smith, N., Gillespie, G., Shaw, W., Burgess, S., Bilbao, G., Curiel, D., 1997. In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer. Nature biotechnology 15, 462-466.   DOI
69 Camber, O., Edman, P., Gurny, R., 1987. Influence of sodium hyaluronate on the meiotic effect of pilocarpine in rabbits. Current eye research 6, 779-784.   DOI
70 Catterall, J., Jones, L., Turner, G., 1999. Membrane protein glycosylation and CD44 content in the adhesion of human ovarian cancer cells to hyaluronan. Clinical and Experimental Metastasis 17, 583-591.   DOI
71 Cho, K., Chung, T., Kim, B., Kim, M., Lee, J., Wee, W., Cho, C., 2003. Release of ciprofloxacin from poloxamer-graft-hyaluronic acid hydrogels in vitro. International Journal of Pharmaceutics 260, 83-91.   DOI
72 Choi, K.Y., Chung, H., Min, K.H., Yoon, H.Y, Kim, K., Park, J.H., Kwon, I.C., Jeong, S.Y., 2010. Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials 31, 106-114.   DOI
73 Chono, S., Li, S., Conwell, C., Huang, L., 2008. An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. Journal of Controlled Release 131, 64-69.   DOI
74 Chun, K.W., Lee, J.B., Kim, S.H., Park, T.G., 2005. Controlled release of plasmid DNA from photo-cross-linked pluronic hydrogels. Biomaterials 26, 3319-3326.   DOI
75 Auzenne, E., Ghosh, S., Khodadadian, M., Rivera, B., Farquhar, D., Price, R., Ravoori, M., Kundra, V., Freedman, R., Klostergaard, J., 2007. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44 (+) human ovarian carcinoma xenografts. Neoplasia (New York, NY) 9, 479.   DOI
76 Coradini, D., Pellizzaro, C., Miglierini, G., Daidone, M., Perbellini, A., 1999. Hyaluronic acid as drug delivery for sodium butyrate: improvement of the anti-proliferative activity on a breast-cancer cell line. International Journal of Cancer 81, 411-416.   DOI
77 Culty, M., Shizari, M., Thompson, E., Underhill, C., 1994. Binding and degradation of hyaluronan by human breast cancer cell lines expressing different forms of CD44: correlation with invasive potential. Journal of cellular physiology 160, 275-286.   DOI
78 Akima, K., Ito, H., Iwata, Y., Matsuo, K., Watari, N., Yanagi, M., Hagi, H., Oshima, K., Yagita, A., Atomi, Y., 1996. Evaluation of antitumor activities of hyaluronate binding antitumor drugs: synthesis, characterization and antitumor activity. Journal of Drug Targeting 4, 1-8.   DOI
79 Balazs, E., Denlinger, J., 1993. Viscosupplementation: a new concept in the treatment of osteoarthritis. Journal of rheumatology Supplement 20, 3-9.
80 Balazs, E., Leshchiner, A., 1987. Cross-linked gels of hyaluronic acid and products containing such gels. In: Google Patents.
81 Barbault-Foucher, S., Gref, R., Russo, P., Guechot, J., Bochot, A., 2002. Design of poly--caprolactone nanospheres coated with bioadhesive hyaluronic acid for ocular delivery. Journal of Controlled Release 83, 365-375.   DOI
82 Bernatchez, S.F., 1993. Ophthalmology.
83 Bothner, H., Wik, O., 1987. Rheology of hyaluronate. Acta Oto-Laryngologica 104, 25-30.
84 Tammi, R., Ripellino, J., Margolis, R., Tammi, M., 1988. Localization of epidermal hyaluronic acid using the hyaluronate binding region of cartilage proteoglycan as a specific probe. Journal of Investigative Dermatology 90, 412-414.   DOI
85 Surace, C., Arpicco, S., Dufay -Wojcicki, A., Marsaud, V., Bouclier, C., Clay, D., Cattel, L., Renoir, J., Fattal, E., 2009. Lipoplexes targeting the CD44 hyaluronic acid receptor for efficient transfection of breast cancer cells. Molecular Pharmaceutics 6, 1062-1073.   DOI
86 Surendrakumar, K., Martyn, G., Hodgers, E., Jansen, M., Blair, J., 2003. Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. Journal of Controlled Release 91, 385-394.   DOI
87 Takei, Y., Maruyama, A., Ferdous, A., Nishimura, Y., Kawano, S., Ikejima, K., Okumura, S., Asayama, S., Nogawa, M., Hashimoto, M., 2004. Targeted gene delivery to sinusoidal endothelial cells: DNA nanoassociate bearing hyaluronanglycocalyx. The FASAB Journal 18: 699-701.   DOI
88 Tracy, M., 1998. Development and scale-up of a microsphere protein delivery system. Biotechnology progress 14, 108-115.   DOI
89 Turker, S., Onur, E., Ozer, Y., 2004. Nasal route and drug delivery systems. Pharmacy World & Science 26, 137-142.   DOI
90 Ugwoke, M., Agu, R., Verbeke, N., Kinget, R., 2005. Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Advanced drug delivery reviews 57, 1640-1665.   DOI
91 Prisell, P., Camber, O., Hiselius, J., Norstedt, G., 1992. Evaluation of hyaluronan as a vehicle for peptide growth factors. International Journal of Pharmaceutics 85, 51-56.   DOI
92 Ohri, R., Hahn, S., Hoffman, A., Stayton, P., Giachelli, C., 2004. Hyaluronic acid grafting mitigates calcification of glutaraldehyde-fixed bovine pericardium. Journal of Biomedical Materials Research Part A 70, 328-334.
93 Moriyama, K., Ooya, T., Yui, N., 1999. Hyaluronic acid grafted with poly (ethylene glycol) as a novel peptide formulation. Journal of Controlled Release 59, 77-86.   DOI
94 Necas, J., Bartosikova, L., Brauner, P., Kolar, J., 2008. Hyaluronic acid (hyaluronan): a review. Veterinarni Medicina 53, 397-411.
95 Oh, E., Park, K., Kim, K., Kim, J., Yang, J., Kong, J., Lee, M., Hoffman, A., Hahn, S., 2010. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. Journal of Controlled Release 141, 2-12.   DOI
96 Park, J., Chakrabarti, B., 1978. Conformational transition of hyaluronic acid carboxylic group participation and thermal effect. Biochimica et Biophysica Acta (BBA)-General Subjects 541, 263-269.   DOI
97 Peer, D., Margalit, R., 2004. Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. International Journal of Cancer 108, 780-789.   DOI
98 Prestwich, G., Marecak, D., Marecek, J., Vercruysse, K., Ziebell, M., 1998. Controlled chemical modification of hyaluronic acid: synthesis, applications, and biodegradation of hydrazide derivatives. Journal of Controlled Release 53, 93-103.   DOI
99 Price, R., Berry, M., Navsaria, H., 2007. Hyaluronic acid: the scientific and clinical evidence. Journal of Plastic, Reconstructive & Aesthetic Surgery 60, 1110-1119.   DOI
100 Jiang, H., Wang, Y., Huang, Q., Li, Y., Xu, C., Zhu, K., Chen, W., 2005. Biodegradable hyaluronic acid/N-carboxyethyl chitosan/protein ternary complexes as implantable carriers for controlled protein release. Macromolecular bioscience 5, 1226-1233.   DOI
101 Johnson, O., Cleland, J., Lee, H., Charnis, M., Duenas, E., Jaworowicz, W., Shepard, D., Shahzamani, A., Jones, A., Putney, S., 1996. A month-long effect from a single injection of microencapsulated human growth hormone. Nature Medicine 2, 795-799.   DOI
102 Kim, A., 2005. Delivery of a vector encoding mouse hyaluronan synthase 2 via a crosslinked hyaluronan film. Biomaterials 26, 1585-1593.   DOI
103 Kim, A., Checkla, D., Dehazya, P., Chen, W., 2003. Characterization of DNA-hyaluronan matrix for sustained gene transfer. Journal of Controlled Release 90, 81-95.   DOI
104 Kim, E.-J., Shim, G., Kim, K., Kwon, I.C., Oh, Y.-K., Shim, C.-K., 2009. Hyaluronic acid complexed to biodegradable poly Larginine for targeted delivery of siRNAs. The journal of gene medicine 11, 791-803.   DOI
105 Kim, M., Park, T., 2002. Temperature-responsive and degradable hyaluronic acid/Pluronic composite hydrogels for controlled release of human growth hormone. Journal of Controlled Release 80, 69-77.   DOI
106 Kim, S., Hahn, S., Kim, M., Kim, D., Lee, Y., 2005. Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticles. Journal of Controlled Release 104, 323-335.   DOI
107 Kobayashi, Y., Okamoto, A., Nishinari, K., 1994. Viscoelasticity of hyaluronic acid with different molecular weights. Biorheology 31, 235-244.   DOI